Mohammed Bahey-El-Din

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8836169/publications.pdf

Version: 2024-02-01

30	684	471509 17	552781 26
papers	citations	h-index	g-index

30	30	30	931
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Plant DNA barcoding and metabolomics for comprehensive discrimination of German Chamomile from its poisonous adulterants for food safety. Food Control, 2022, 136, 108840.	5.5	8
2	Bacterial Ghosts of Pseudomonas aeruginosa as a Promising Candidate Vaccine and Its Application in Diabetic Rats. Vaccines, 2022, 10, 910.	4.4	2
3	Recombinant Ax21 protein is a promising subunit vaccine candidate against Stenotrophomonas maltophilia in a murine infection model. Vaccine, 2021, 39, 4471-4480.	3.8	3
4	Immunization with the basic membrane protein (BMP) family ABC transporter elicits protection against Enterococcus faecium in a murine infection model. Microbes and Infection, 2020, 22, 127-136.	1.9	2
5	Recombinant N-terminal outer membrane porin (OprF) of Pseudomonas aeruginosa is a promising vaccine candidate against both P. aeruginosa and some strains of Acinetobacter baumannii. International Journal of Medical Microbiology, 2020, 310, 151415.	3.6	26
6	Vancomycin-functionalized Eudragit-based nanofibers: Tunable drug release and wound healing efficacy. Journal of Drug Delivery Science and Technology, 2020, 58, 101812.	3.0	12
7	Combining hydrophilic chemotherapy and hydrophobic phytotherapy via tumor-targeted albuminâ€“QDs nano-hybrids: covalent coupling and phospholipid complexation approaches. Journal of Nanobiotechnology, 2019, 17, 7.	9.1	36
8	Immunization with the ferric iron-binding periplasmic protein HitA provides protection against Pseudomonas aeruginosa in the murine infection model. Microbial Pathogenesis, 2019, 131, 181-185.	2.9	18
9	Enhanced transdermal permeability of Terbinafine through novel nanoemulgel formulation; Development, inÂvitro and inÂvivo characterization. Future Journal of Pharmaceutical Sciences, 2018, 4, 18-28.	2.8	58
10	Immunization with the outer membrane proteins OmpK17 and OmpK36 elicits protection against Klebsiella pneumoniae in the murine infection model. Microbial Pathogenesis, 2018, 119, 12-18.	2.9	22
11	Lactoferrin-tagged quantum dots-based theranostic nanocapsules for combined COX-2 inhibitor/herbal therapy of breast cancer. Nanomedicine, 2018, 13, 2637-2656.	3.3	63
12	Layer-by-layer gelatin/chondroitin quantum dots-based nanotheranostics: combined rapamycin/celecoxib delivery and cancer imaging. Nanomedicine, 2018, 13, 1707-1730.	3.3	30
13	Mycothiol acetyltransferase (Rv0819) ofMycobacterium tuberculosisis a potential biomarker for direct diagnosis of tuberculosis using patient serum specimens. Letters in Applied Microbiology, 2017, 65, 504-511.	2.2	3
14	Novel lecithin-integrated liquid crystalline nanogels for enhanced cutaneous targeting of terconazole: development, in vitro and in vivo studies. International Journal of Nanomedicine, 2016, Volume 11, 5531-5547.	6.7	42
15	Listeria monocytogenesmutants defective in gallbladder replication represent safety-enhanced vaccine delivery platforms. Human Vaccines and Immunotherapeutics, 2016, 12, 2059-2063.	3.3	10
16	Recombinant expression of the alternate reading frame protein (ARFP) of hepatitis C virus genotype 4a (HCV-4a) and detection of ARFP and anti-ARFP antibodies in HCV-infected patients. Archives of Virology, 2015, 160, 1939-1952.	2.1	10
17	Successful detection, expression and purification of the alternatively spliced truncated Sm14 antigen of an Egyptian strain of Schistosoma mansoni. Journal of Helminthology, 2015, 89, 764-768.	1.0	2
18	Fusion protein comprised of the two schistosomal antigens, Sm14 and Sm29, provides significant protection against Schistosoma mansoni in murine infection model. BMC Infectious Diseases, 2015, 15, 147.	2.9	23

#	Article	IF	Citations
19	Two-tiered biological containment strategy forLactococcus lactis-based vaccine or immunotherapy vectors. Human Vaccines and Immunotherapeutics, 2014, 10, 333-337.	3.3	3
20	Combination of the two schistosomal antigens Sm14 and Sm29 elicits significant protection against experimental Schistosoma mansoni infection. Experimental Parasitology, 2014, 145, 51-60.	1.2	20
21	Vaccination Studies: Detection of a Listeria monocytogenes-Specific T Cell Immune Response Using the ELISPOT Technique. Methods in Molecular Biology, 2014, 1157, 263-274.	0.9	1
22	A mutant in the Listeria monocytogenes Fur-regulated virulence locus (frvA) induces cellular immunity and confers protection against listeriosis in mice. Journal of Medical Microbiology, 2013, 62, 185-190.	1.8	19
23	Lactococcus lactis-based vaccines from laboratory bench to human use: An overview. Vaccine, 2012, 30, 685-690.	3.8	56
24	Lactococcus lactis-based vaccines: Current status and future perspectives. Hum Vaccin, 2011, 7, 106-109.	2.4	23
25	Lactococcus lactis as a Cell Factory for Delivery of Therapeutic Proteins. Current Gene Therapy, 2010, 10, 34-45.	2.0	56
26	Expression of two Listeria monocytogenes antigens (P60 and LLO) in Lactococcus lactis and examination for use as live vaccine vectors. Journal of Medical Microbiology, 2010, 59, 904-912.	1.8	23
27	<p class="p1"> Efficacy of aLactococcus lactisÎ”pyrGvaccine delivery platform expressing chromosomally integratedhlyfromListeria monocytogenes. Bioengineered Bugs, 2010, 1, 66-74.	1.7	27
28	Lactococcus lactis: from the dairy industry to antigen and therapeutic protein delivery. Discovery Medicine, 2010, 9, 455-61.	0.5	12
29	Nisin inducible production of listeriolysin O in Lactococcus lactis NZ9000. Microbial Cell Factories, 2008, 7, 24.	4.0	27
30	Lactococcus lactis-expressing listeriolysin O (LLO) provides protection and specific CD8+ T cells against Listeria monocytogenes in the murine infection model. Vaccine, 2008, 26, 5304-5314.	3.8	47